- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Nebivolol has beneficial metabolic profile in diabetics with high BP compared to atenolol: Study
![Nebivolol has beneficial metabolic profile in diabetics with high BP compared to atenolol: Study Nebivolol has beneficial metabolic profile in diabetics with high BP compared to atenolol: Study](https://medicaldialogues.in/h-upload/2021/11/30/750x450_165198-hypertension-with-diabetes.webp)
Pakistan: Nebivolol is beneficial over atenolol with regards to glycemic control and serum lipid profile in type 2 diabetes patients with concomitant hypertension, reveals a recent study published in the Pakistan Journal of Pharmaceutical Sciences.
Blood pressure control in patients with hypertension and metabolic abnormalities is challenging as many antihypertensive drugs adversely affect metabolism. Nebivolol is a third-generation β-blocker, with the highest β(1) selectivity and nitric-oxide-derived vasodilatation. It also shows antioxidant and antiproliferative property that has a beneficial metabolic profile versus second-generation β blockers like atenolol.
Against the above background, Abdul Majid, Department of Cardiology Sheikh Zayed Medical College/Hospital Rahim Yar Khan, Punjab, Pakistan, and colleagues aimed to evaluate the effect of nebivolol and atenolol on glycemic control and lipid profile in type 2 diabetes patients with concomitant hypertension.
For this purpose, they conducted a 12 week double-blind randomized clinical trial. The patients were randomly assigned into two groups. Patients in group A were given tablet nebivolol 5-10mg while patients in group B were given tablet Atenolol 25-50mg/daily for a period of 12 weeks. Pre and post data were analyzed by SPSS 20.
Key findings include:
- After 12 weeks, both drugs lowered blood pressure significantly i.e. nebivolol (SBP from152±12 to130±14, DBP from 95±12 to78±8.5) Atenolol (SBP from148±16.5 to 128±15.5, DBP from 90±10.5 to 82±12).
- Similarly, both Nebivolol and Atenolol did not any significant effect on glycemic control and lipid profile at 12 weeks within groups.
- When comparison was done between two groups, Nebivolol significantly reduced blood sugar, HbA1c, total cholesterol, triglycerides, LDL-Cholesterol, and HDL-Cholesterol as compared to atenolol.
The researchers concluded, "comparison with atenolol, Nebivolol has a beneficial effect on glycemic control and serum lipid profile."
Reference:
Majid A, Javed A, Hussain M, Faisal Z, Elahi A, Akhtar L. Effect of nebivolol beneficial on lipid profile and glycemic control in comparison with Atenolol in patients with type 2 DM with concomitant hypertension. Pak J Pharm Sci. 2021 Sep;34(5(Supplementary)):1891-1895. PMID: 34836856.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751